Connect with us

Hi, what are you looking for?

Wednesday, Aug 17, 2022
Mugglehead Magazine
Alternative investment news based in Vancouver, B.C.

International

Denmark extends trial for cannabis patients, makes production permanent

Denmark’s parliament ruled its pilot program would continue after it expires at the end of this year

Denmark extends trial for cannabis patients, makes production permanent
Image via Aurora Nordic, a subsidiary of Aurora Cannabis Inc

Danish patients will be able to access medical cannabis for at least another four years, and companies in the country producing the plant for medical purposes can operate permanently.

Late Tuesday, a broad majority of parties voted in Danish parliament to continue a trial scheme for medical cannabis access, which expires at the end of the year.

The ruling Social Democrats, the Liberals, the Danish People’s Party, the Socialist People’s Party, the Unity List, the New Bourgeois, Liberal Alliance, the Alternative, the Christian Democrats and the Free Greens all voted in favour.

Denmark’s curious division of production and access will continue, as foreign firms will provide domestic supply via import, and companies within Danish borders ship medical weed to other European markets.

The current trial will expire at the end of 2021, but its continuation is mandated by law thereafter, according to the Danish Ministry of Health The government will submit bills this fall for adoption by the end of the year.

Only a select few Good Manufacturing Practices-certified producers are approved to supply Denmark’s medical patients, including Netherlands-based Bedrocan, as well as Canadian firms Aurora Cannabis Inc. (TSX and NYSE: ACB) and MediPharm Labs Corp. (TSX: LABS).

Read more: MediPharm enters Denmark’s medical cannabis market

Denmark opened medical cannabis access for patients in 2018 as part of a four-year pilot program. Its purpose is to offer patients with legal, safe products and provide national health authorities with patient data.

That information was to be analyzed to understand usage and efficacy at the end of the trial period to consider establishing a permanent medical market, but a permanent domestic plan hasn’t been mentioned yet.

The program is only eligible for patients suffering from multiple sclerosis, spinal cord damage, cancer and neuropathic pain.

 

Follow Mugglehead on Twitter

Like Mugglehead on Facebook

Follow Nick Laba on Twitter

nick@mugglehead.com

Click to comment

Leave a Reply

Your email address will not be published.

You May Also Like

Business

This April, Pure Extracts Manufacturing Corp. received an IPO from the Nova Scotia Liquor Corporation Cannabis for its vapes and hemp-based edibles

Canada

The study was the largest of its kind to date, examining the impact of medical cannabis on anxiety and depression in 7,362 Canadian patients

Business

The oil is now available at the Jardin, Vegas Tree House, and Exhale pot shops in Las Vegas

Business

The study also found that seven out of ten patients did not suffer from adverse effects